% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hennrich:302329,
      author       = {U. Hennrich$^*$ and L. Wagner$^*$ and H. Tas$^*$ and L.
                      Kovacs$^*$ and M. Benesova-Schäfer$^*$},
      title        = {{R}evolutionizing {P}rostate {C}ancer {D}etection: {T}he
                      {R}ole of {A}pproved {PSMA}-{PET} {I}maging {A}gents.},
      journal      = {Pharmaceuticals},
      volume       = {18},
      number       = {6},
      issn         = {1424-8247},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2025-01324},
      pages        = {906},
      year         = {2025},
      note         = {#EA:W630#LA:E270#},
      abstract     = {Locametz®/Illuccix®/GozellixTM (Novartis AG (Basel,
                      Switzerland) and Telix Pharmaceuticals, Ltd. (Melbourne,
                      Australia), all three [68Ga]Ga-PSMA-11),
                      Pylarify®/Pylclari® (Progenics Pharmaceuticals, Inc. (New
                      York, USA) and Curium PET France SA (Paris, France), both
                      [18F]DCFPyL), Radelumin® (ABX GmbH (Radeberg, Germany),
                      [18F]PSMA-1007), and Posluma® (Blue Earth Diagnostics, Ltd.
                      (Oxford, UK), [18F]rhPSMA-7.3) are four approved PSMA-PET
                      imaging agents that have significantly advanced the
                      diagnosis and management of prostate cancer. These agents
                      offer a new level of precision and accuracy, enabling
                      clinicians to detect prostate cancer with enhanced
                      sensitivity. As a result, they play a critical role in
                      improving detection, staging, and management, ultimately
                      enhancing clinical outcomes for patients. Their use in
                      routine clinical practice is expected to increase diagnostic
                      precision and provide clearer pathways for personalized
                      therapy. This review offers a comprehensive chemical,
                      pharmaceutical, and medicinal overview, discusses
                      comparative studies, and highlights additional highly
                      relevant candidates for prostate cancer detection.},
      subtyp        = {Review Article},
      keywords     = {EMA approval (Other) / FDA approval (Other) / GozellixTM
                      (Other) / Illuccix® (Other) / Locametz® (Other) / PET
                      diagnostics (Other) / PSMA (Other) / Posluma® (Other) /
                      Pylarify® (Other) / Pylclari® (Other) / Radelumin®
                      (Other) / fluorine-18 (Other) / gallium-68 (Other) /
                      prostate cancer (Other)},
      cin          = {W630 / E270},
      ddc          = {610},
      cid          = {I:(DE-He78)W630-20160331 / I:(DE-He78)E270-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40573302},
      doi          = {10.3390/ph18060906},
      url          = {https://inrepo02.dkfz.de/record/302329},
}